In the past week, RNAZ stock has gone down by -5.87%, with a monthly decline of -70.65% and a quarterly plunge of -78.95%. The volatility ratio for the week is 13.82%, and the volatility levels for the last 30 days are 13.49% for TransCode Therapeutics Inc The simple moving average for the past 20 days is -43.87% for RNAZ’s stock, with a -83.03% simple moving average for the past 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
RNAZ has 36-month beta value of 0.72. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAZ is 0.70M, and currently, short sellers hold a 7.49% ratio of that float. The average trading volume of RNAZ on January 01, 2025 was 53.11K shares.
RNAZ) stock’s latest price update
The stock of TransCode Therapeutics Inc (NASDAQ: RNAZ) has decreased by -10.37 when compared to last closing price of 3.76.Despite this, the company has seen a loss of -5.87% in its stock price over the last five trading days. prnewswire.com reported 2024-12-18 that Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients currently being evaluated for eligibility in Cohort 3 PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results BOSTON, Dec. 18, 2024 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers.
RNAZ Trading at -70.12% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.58% of loss for the given period.
Volatility was left at 13.49%, however, over the last 30 days, the volatility rate increased by 13.82%, as shares sank -63.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -83.34% lower at present.
During the last 5 trading sessions, RNAZ fell by -5.87%, which changed the moving average for the period of 200-days by -85.22% in comparison to the 20-day moving average, which settled at $6.00. In addition, TransCode Therapeutics Inc saw -98.45% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
To put it simply, TransCode Therapeutics Inc (RNAZ) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
